SARS-CoV-2 Infection Drives a Glycan Switch of Peripheral T Cells at Diagnosis
- 15 September 2021
- journal article
- research article
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 207 (6) , 1591-1598
Abstract
COVID-19 is a highly selective disease in which SARS-CoV-2 infection can result in different clinical manifestations ranging from asymptomatic/mild to severe disease that requires hospitalization. In this study, we demonstrated that SARS-CoV-2 infection results in a glycosylation reprogramming of circulating lymphocytes at diagnosis. We identified a specific glycosignature of T cells, defined upon SARS-CoV-2 infection and apparently triggered by a serological factor. This specific glycan switch of T cells is detected at diagnosis being more pronounced in asymptomatic patients. We further demonstrated that asymptomatic patients display an increased expression of a viral-sensing receptor through the upregulation of DC-SIGN in monocytes. We showed that higher levels of DC-SIGN in monocytes at diagnosis correlates with better COVID-19 prognosis. This new evidence pave the way to the identification of a novel glycan-based response in T cells that may confer protection against SARS-CoV-2 infection in asymptomatic patients, highlighting a novel prognostic biomarker and potential therapeutic target. Key Points T cells from COVID-19 patients display less complex N-glycans at diagnosis. IL-2 is a putative driver of glycan switch in COVID-19 patients. DC-SIGN expression in monocytes at diagnosis predicts poor disease course.Keywords
All Related Versions
Funding Information
- MEC | Fundação para a Ciência e a Tecnologia (Project #6 RESEARCH 4 COVID)
- MEC | Fundação para a Ciência e a Tecnologia (SFRH/BD/128874/2017)
- MEC | Fundação para a Ciência e a Tecnologia (PD/BD/135452/2017)
This publication has 29 references indexed in Scilit:
- Bitter-sweet symphony: glycan–lectin interactions in virus biologyFEMS Microbiology Reviews, 2014
- Dysregulation of T cell receptor N-glycosylation: a molecular mechanism involved in ulcerative colitisHuman Molecular Genetics, 2013
- Roles for major histocompatibility complex glycosylation in immune functionSeminars in Immunopathology, 2012
- Interleukin‐2, Interleukin‐7, T cell‐mediated autoimmunity, and N‐glycosylationAnnals of the New York Academy of Sciences, 2012
- Genetics and the environment converge to dysregulate N-glycosylation in multiple sclerosisNature Communications, 2011
- T‐cell growth, cell surface organization, and the galectin–glycoprotein latticeImmunological Reviews, 2009
- Protein-glycan interactions in the control of innate and adaptive immune responsesNature Immunology, 2008
- Differential glycosylation of TH1, TH2 and TH-17 effector cells selectively regulates susceptibility to cell deathNature Immunology, 2007
- DC-SIGN and DC-SIGNR Interact with the Glycoprotein of Marburg Virus and the S Protein of Severe Acute Respiratory Syndrome CoronavirusJournal of Virology, 2004
- Alteration of Cell Surface Sialylation Regulates Antigen-Induced Naive CD8+ T Cell ResponsesThe Journal of Immunology, 2004